Vimarsana
Biggest News Aggregation in the World

Proteomic Profiling News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Proteomic Profiling. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Proteomic Profiling Today - Breaking & Trending Today

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting - Vimarsana News

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

Published: April 12, 2024

Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndrome  NOVATO, Calif., April 12, 2024 --...

Source: marketscreener.com
Related Topics:
United StatesKemia OlugemoMelanie BrandaburRachael Elizabeth HawtinCarolyn WangJoshua HigaAmerican Academy Of Neurology MeetingExchange CommissionUltragenyx Pharmaceutical IncAnnual American AcademyNeurology MeetingClinical ActivityInvestigational Antisense OligonucleotidePatients With AngelmanEmerging ScienceProteomic ProfilingAngelman SyndromeDisease Associated BiomarkerChild NeurologyDevelopmental NeurologyClinical CharacteristicsCreatine Transporter DeficiencyFinal ResultsVigilan ObservationalLooking Statements
EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023 - Vimarsana News

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023

Published: July 11, 2023

/PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings on its...

Source: prnewswire.com
Related Topics:
District Of ColumbiaUnited StatesSouth KoreaUnited KingdomNew ZealandUniversity CollegeNew South WalesNoord HollandGreat BritainMichael IrizarryLibby HolmanHaruo NaitoUniversity College LondonHealth Services ResearchAlzheimer Network Trials UnitNational Institutes Of HealthClinical ResearchPrnewswire Eisai CoDrug AdministrationEisai Co LtdEisai Europe LtdCritical Path For Alzheimer Disease ConsortiumDrug DevelopmentPublic Relations DepartmentAlzheimer Clinical Trial Consortium